• Explore /
  • Poster
  • / Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.

Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.

Abstract Video & Slides Poster

Authors

Sun Young Rha

Sun Young Rha

Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea

Sun Young Rha , Toni K. Choueiri , Vsevolod B. Matveev , Anna Alyasova , Sung-Hoo Hong , Teresa Alonso Gordoa , Howard Gurney , Georg A. Bjarnason , Tomas Buchler , Paolo Pedrazzoli , Toshio Takagi , Se Hoon Park , Jae-Lyun Lee , Rodolfo F. Perini , Cixin He , Jodi A. McKenzie , Masatoshi Eto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02811861

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 338)

DOI

10.1200/JCO.2022.40.6_suppl.338

Abstract #

338

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Nizar M. Tannir

First Author: Viktor Grünwald

First Author: Michael B. Atkins

First Author: Vicky Makker